The non-ATP competitive AKT inhibitor TAS-117 has been tested in vitro in combination with chemotherapeutic and targeted agents in A2780 ovarian cancer cells and xenografts, with results indicating that TAS-117 effectively enhances the cytotoxic effects of fluorouracil and cisplatin in vitro, and improves the anti-tumor effect of carboplatin in vivo[139]. Here, AKT1 is linked to ovarian carcinoma.